The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
The androgen receptor gene mutations database: 2012 update
Open accessAbstract
The current version of the androgen receptor gene (AR) mutations database is described. A major change to the database is that the nomenclature and numbering scheme now conforms to all Human Genome Variation Society norms. The total number of reported mutations has risen from 605 to 1,029 since 2004. The database now contains a number of mutations that are associated with prostate cancer (CaP) treatment regimens, while the number of AR mutations found in CaP tissues has more than doubled from 76 to 159. In addition, in a number of androgen insensitivity syndrome (AIS) and CaP cases, multiple mutations have been found within the same tissue samples. For the first time, we report on a disconnect within the AIS phenotype-genotype relationship among our own patient database, in that over 40% of our patients with a classic complete AIS or partial AIS phenotypes did not appear to have a mutation in their AR gene. The implications of this phenomenon on future locus-specific mutation database (LSDB) development are discussed, together with the concept that mutations can be associated with both loss- and gain-of-function, and the effect of multiple AR mutations within individuals. The database is available on the internet (http://androgendb.mcgill.ca), and a web-based LSDB with the variants using the Leiden Open Variation Database platform is available at http://www.lovd.nl/AR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Gene Mutation Database (HGMD®): 2003 update: HGMD 2003 UPDATE
Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D., Shiel, J. A., Thomas, N. S. T., Abeysinghe, S., Krawczak, M., & Cooper, D. N. (2003) · Human Mutation · doi:10.1002/humu.10212 · Cited by 1,829
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
LOVD v.2.0: the next generation in gene variant databases
Fokkema, I. F. A. C., Taschner, P. E. M., Schaafsma, G. C. P., Celli, J., Laros, J. F. J., & den Dunnen, J. T. (2011) · Human Mutation · doi:10.1002/humu.21438 · Cited by 1,048
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Lubahn, D. B., Joseph, D. R., Sar, M., Tan, J.-A., Higgs, H. N., Larson, R. E., French, F. S., & Wilson, E. M. (1988) · Molecular Endocrinology · doi:10.1210/mend-2-12-1265 · Cited by 570
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
Edwards, J., Krishna, N. S., Grigor, K. M., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601127 · Cited by 424
Williams Textbook of Endocrinology
Niculescu, D. (2008) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2008.127 · Cited by 372
Mhatre, A. N., Trifiro, M. A., Kaufman, M., Kazemi-Esfarjani, P., Figlewicz, D., Rouleau, G., & Pinsky, L. (1993) · Nature Genetics · doi:10.1038/ng1093-184 · Cited by 357
Self-citationAhmed, S. F., Cheng, A., Dovey, L., Hawkins, J. R., Martin, H., Rowland, J., Shimura, N., Tait, A. D., & Hughes, I. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.2.6337 · Cited by 315
The androgen receptor gene mutations database (ARDB): 2004 update
Gottlieb, B., Beitel, L. K., Wu, J. H., & Trifiro, M. (2004) · Human Mutation · doi:10.1002/humu.20044 · Cited by 311
Self-citation
Cited by
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Androgen receptor: structure, role in prostate cancer and drug discovery
Tan, M. E., Li, J., Xu, H. E., Melcher, K., & Yong, E.-L. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 943
Krausz, C., & Riera-Escamilla, A. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0003-3 · Cited by 926
RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
Miyamoto, D. T., Zheng, Y., Wittner, B. S., Lee, R. J., Zhu, H., Broderick, K. T., Desai, R., Fox, D. B., Brannigan, B. W., Trautwein, J., et al. (2015) · Science · doi:10.1126/science.aab0917 · Cited by 705
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Role of Androgen Receptor in Prostate Cancer: A Review
Fujita, K., & Nonomura, N. (2019) · The World Journal of Men's Health · doi:10.5534/wjmh.180040 · Cited by 483
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
Eggers, S., Sadedin, S., van den Bergen, J. A., Robevska, G., Ohnesorg, T., Hewitt, J., Lambeth, L., Bouty, A., Knarston, I. M., Tan, T. Y., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1105-y · Cited by 401
Menden, M. P., Wang, D., Mason, M. J., Szalai, B., Bulusu, K. C., Guan, Y., Yu, T., Kang, J., Jeon, M., Wolfinger, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09799-2 · Cited by 363
Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives
Khan, M. J., Ullah, A., & Basit, S. (2019) · The Application of Clinical Genetics · doi:10.2147/tacg.s200341 · Cited by 354
Nguyen, H. M., Vessella, R. L., Morrissey, C., Brown, L. G., Coleman, I. M., Higano, C. S., Mostaghel, E. A., Zhang, X., True, L. D., Lam, H.-M., et al. (2017) · The Prostate · doi:10.1002/pros.23313 · Cited by 300
Jiao, S.-Y., Yang, Y.-H., & Chen, S.-R. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmaa034 · Cited by 276
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Aurilio, G., Cimadamore, A., Mazzucchelli, R., Lopez-Beltran, A., Verri, E., Scarpelli, M., Massari, F., Cheng, L., Santoni, M., & Montironi, R. (2020) · Cells · doi:10.3390/cells9122653 · Cited by 258
Structure of the homodimeric androgen receptor ligand-binding domain
Nadal, M., Prekovic, S., Gallastegui, N., Helsen, C., Abella, M., Zielinska, K., Gay, M., Vilaseca, M., Taulès, M., Houtsmuller, A. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms14388 · Cited by 193
Nordenström, A., Ahmed, S. F., van den Akker, E., Blair, J., Bonomi, M., Brachet, C., Broersen, L. H. A., Claahsen-van der Grinten, H. L., Dessens, A. B., Gawlik, A., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0073 · Cited by 108
Mitochondrial localization, import, and mitochondrial function of the androgen receptor
Bajpai, P., Koc, E., Sonpavde, G., Singh, R., & Singh, K. K. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006727 · Cited by 99
“Because AR has both NLS and MLS, it is plausible that the shunting of AR between nucleus and mitochondria plays a major role in prostate tumorigenesis.”
BackgroundInfluentialDong, J., Wu, Z., Wang, D., Pascal, L. E., Nelson, J. B., Wipf, P., & Wang, Z. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0432 · Cited by 49
“Around 70 NTD cofactors have been reported (21).”
BackgroundMethodBramble, M. S., Lipson, A., Vashist, N., & Vilain, E. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23832 · Cited by 42
Metadata
- Authors
- Gottlieb, B., Beitel, L. K., Nadarajah, A., Paliouras, M., & Trifiro, M.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2012-03-13
- Volume
- 33
- Issue
- 5
- Pages
- 887-894
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W2055655957
- Cited by
- 512
- References
- 47
- FWCI
- 23.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.